TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
1.260
+0.050 (4.13%)
At close: May 8, 2026, 4:00 PM EDT
1.300
+0.040 (3.17%)
After-hours: May 8, 2026, 7:45 PM EDT

TScan Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
9.1410.332.8221.0513.5410.14
Revenue Growth (YoY)
106.65%266.65%-86.62%55.52%33.47%834.65%
Gross Profit
9.1410.332.8221.0513.5410.14
Selling, General & Admin
31.5763.9860.5726.3520.3513.83
Research & Development
106.27228.3214.788.1559.8244.95
Total Operating Expenses
137.84292.28275.27114.5180.1758.78
Operating Income
-128.7-135.81-134.82-93.46-66.64-48.64
Interest Income
7.188.8212.0781.590.02
Interest Expense
-2.78-2.77-3.65-3.76-1.18-
Other Non-Operating Income (Expense)
---1.09---
Total Non-Operating Income (Expense)
4.46.057.324.240.420.02
Pretax Income
-124.31-129.77-127.5-89.22-66.22-48.63
Net Income
-124.31-129.77-127.5-89.22-66.22-48.63
Net Income to Common
-124.31-129.77-127.5-89.22-66.22-48.63
Shares Outstanding (Basic)
130130112662412
Shares Outstanding (Diluted)
130130112662412
Shares Change (YoY)
7.61%15.88%70.72%172.78%106.20%1173.20%
EPS (Basic)
-0.96-1.00-1.14-1.36-2.75-4.17
EPS (Diluted)
-0.96-1.00-1.14-1.36-2.75-4.17
Shares Outstanding
55.8256.956.5947.8324.2323.91
Free Cash Flow
-124.96-139.73-114.65-64.5-70.73-58.62
Free Cash Flow Per Share
-0.96-1.08-1.02-0.98-2.94-5.03
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-1408.73%-1315.38%-4787.68%-444.00%-492.32%-479.65%
Profit Margin
-1360.61%-1256.81%-4527.66%-423.86%-489.26%-479.49%
FCF Margin
-1367.74%-1353.28%-4071.27%-306.45%-522.56%-578.03%
EBITDA
-125.82-132.95-130.71-88.1-61.5-45.31
EBITDA Margin
-1377.20%-1287.62%-4641.80%-418.53%-454.37%-446.83%
EBIT
-128.7-135.81-134.82-93.46-66.64-48.64
EBIT Margin
-1408.73%-1315.38%-4787.68%-444.00%-492.32%-479.65%
Updated May 6, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q